Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors
Frontiers in Immunology · 27.03.2025 · 16
DOI: 10.3389/fimmu.2025.1549965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 27.03.2025. Verfasst von Wenjia Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carrier Proteins, Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Microsomal triglyceride transfer protein (MTTP) is an essential lipid transfer protein for the synthesis and secretion of very low density lipoprotein (VLDL) in hepatocytes and chylomicrons (CM) in intestinal cells. Further researches have revealed that MTTP exerted its functions in a variety of tissues beyond the liver and intestine, including the heart, neural tissues and antigen-presenting cells. Dysregulation of MTTP expression can lead to many diseases, such as lipid metabolism disorders, insulin resistance and cardiovascular diseases. Despite its importance, research on MTTP in cancer is limited, with no comprehensive pan-cancer studies available.
Methods
MTTP expression was explored with the TIMER 2.0 and Sangerbox databases. The pathological stages and survival analysis of MTTP were analyzed via GEPIA and Kaplan Meier plotter. The gene mutations of MTTP were analyzed by cBioPortal database. The immune landscape of MTTP in the tumor microenvironment(TME) was analyzed using the TIMER 2.0 and single-cell sequencing. Based on the RNA-seq data in TCGA, we constructed GSEA enrichment analysis for MTTP. We identified the pro-tumor and anti-ferroptosis functions of MTTP in gastric cancer (GC) cells by in vitro and in vivo experiments, and analyzed the effect of TME on ferroptosis by single-cell sequencing.
Results
MTTP expression was elevated in at least 1/3 tumors. High expression of MTTP was associated with poor prognosis in most tumors. MTTP levels were significantly correlated with three scores (immune, stromal, and extimate) and immune checkpoints in at least half of tumor types. Single cell sequencing of immune cells showed that MTTP was mainly expressed in macrophages, especially in microglia. MTTP increased in GC and MTTP knockdown limited the proliferation, migration and invasion abilities of GC cells, accompanied by increased sensitivity to ferroptosis. In addition, analyzing the ferroptosis genes associated with MTTP at the single cell level, we found that macrophages may be involved in the ferroptosis process in GC.
Conclusions
Our pan-cancer study emphasizes that MTTP is a promising prognostic and immunotherapeutic biomarker in tumors. High expression of MTTP is correlated with the infiltration of diverse immune cells and regulates ferroptosis in GC cells, providing a potential target for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zitieren
APA
Wang, W., Gao, Y., Liu, Y., Xia, S., Xu, J., Qin, L., Jia, Y., & Qin, Y. (2025). Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1549965
Vancouver
Wang W, Gao Y, Liu Y, Xia S, Xu J, Qin L, et al. Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1549965
BibTeX
@article{Wang2025,
author = {Wang, Wenjia and Gao, Yaping and Liu, Yihan and Xia, Shurui and Xu, Jiayao and Qin, Liwei and Jia, Yongxu and Qin, Yanru},
title = {Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1549965}
}
EUVIMED